Cover Page
The handle
http://hdl.handle.net/1887/136914
holds various files of this Leiden University
dissertation.
Author: Dávila Fajardo, C.L.
Title: Genetic variants contribute to differences in response and toxicity to drugs used in
autoimmune diseases: Rheumatoid arthritis and systemic lupus erythematosus
Genetic variants contribute to differences in response and
toxicity to drugs used in autoimmune diseases:
Rheumatoid arthritis and Systemic lupus erythematosus
The research presented in this thesis was performed at the department of Pharmacy of Hospital Universitario San Cecilio, Granada, Spain, and the department of Clinical Pharmacy and Toxicology of Leiden University Medical Center, Leiden, The Netherlands. Financial support for publication of this thesis was provided by departmental funds from the department of Clinical Pharmacy & Toxicology of the Leiden University Medical Center, Leiden, the Netherlands.
Cover Cristina Lucía Dávila Fajardo
Cover image Shutterstock, 1409838749 Layout Renate Siebes | Proefschrift.nu
Printed by Ridderprint, Alblasserdam
ISBN 978-94-92026-16-3
Genetic variants contribute to differences in response and
toxicity to drugs used in autoimmune diseases:
Rheumatoid arthritis and Systemic lupus erythematosus
Proefschrift
ter verkrijging vande graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties te verdedigen op dinsdag 29 september 2020
klokke 10.00 uur door
Cristina Lucía Dávila Fajardo
geboren te Granada, SpanjePromotor Prof. dr. H.-J. Guchelaar
Copromotor Dr. J.J. Swen
Leden promotiecommissie Prof. dr. A.H.M. van der Helm-van Mil Prof. dr. J. Burggraaf
Chapter 1 General introduction and outline of the thesis 7 Chapter 2 Genetic risk factors for drug-induced liver injury
in rheumatoid arthritis patients using low-dose methotrexate
17
Chapter 3 Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis
39
Chapter 4 Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting anti-TNF treatment outcome
57
Chapter 5 FcGR genetic polymorphisms and the response to
adalimumab in patients with rheumatoid arthritis 71
Chapter 6 Association between -174 Interleukin-6 gene
polymorphism and biological response to rituximab in several systemic autoimmune diseases
91
Chapter 7 Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients
103
Chapter 8 IL2/IL21 region polymorphism influences response to
rituximab in systemic lupus erythematosus patients 117
Chapter 9 Summary 131
Chapter 10 Samenvatting 137
Chapter 11 General discussion and future perspectives 143 Appendix List of publications
